Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

MET mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

MET mutation	Renal Cell Carcinoma	MET mutation	Renal Cell Carcinoma	savolitinib Sensitive: B - Late Trials savolitinib Sensitive : B	savolitinib Sensitive: B - Late Trials savolitinib Sensitive : B
MET mutation	Gastric Cancer	MET mutation	Gastric Cancer	TPX-0022 Sensitive: C2 – Inclusion Criteria TPX-0022 Sensitive : C2	TPX-0022 Sensitive: C2 – Inclusion Criteria TPX-0022 Sensitive : C2
MET mutation	Non Small Cell Lung Cancer	MET mutation	Non Small Cell Lung Cancer	crizotinib Sensitive: C2 – Inclusion Criteria crizotinib Sensitive : C2	crizotinib Sensitive: C2 – Inclusion Criteria crizotinib Sensitive : C2
MET mutation	Renal Cell Carcinoma	MET mutation	Renal Cell Carcinoma	cabozantinib capsule Sensitive: C2 – Inclusion Criteria cabozantinib capsule Sensitive : C2	cabozantinib capsule Sensitive: C2 – Inclusion Criteria cabozantinib capsule Sensitive : C2
MET mutation	Renal Cell Carcinoma	MET mutation	Renal Cell Carcinoma	crizotinib Sensitive: C2 – Inclusion Criteria crizotinib Sensitive : C2	crizotinib Sensitive: C2 – Inclusion Criteria crizotinib Sensitive : C2
MET mutation	Non Small Cell Lung Cancer	MET mutation	Non Small Cell Lung Cancer	MGCD265 Sensitive: C2 – Inclusion Criteria MGCD265 Sensitive : C2	MGCD265 Sensitive: C2 – Inclusion Criteria MGCD265 Sensitive : C2
MET mutation	Renal Cell Carcinoma	MET mutation	Renal Cell Carcinoma	c-MET inhibitor Sensitive: C3 – Early Trials c-MET inhibitor Sensitive : C3	c-MET inhibitor Sensitive: C3 – Early Trials c-MET inhibitor Sensitive : C3
MET mutation	Renal Cell Carcinoma	MET mutation	Renal Cell Carcinoma	sunitinib Sensitive: C3 – Early Trials sunitinib Sensitive : C3	sunitinib Sensitive: C3 – Early Trials sunitinib Sensitive : C3
MET mutation	Renal Cell Carcinoma	MET mutation	Renal Cell Carcinoma	everolimus Sensitive: C3 – Early Trials everolimus Sensitive : C3	everolimus Sensitive: C3 – Early Trials everolimus Sensitive : C3
MET mutation	Renal Cell Carcinoma	MET mutation	Renal Cell Carcinoma	GSK1363089 Sensitive: C3 – Early Trials GSK1363089 Sensitive : C3	GSK1363089 Sensitive: C3 – Early Trials GSK1363089 Sensitive : C3
MET mutation	Non Small Cell Lung Cancer	MET mutation	Non Small Cell Lung Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
MET mutation	Renal Cell Carcinoma	MET mutation	Renal Cell Carcinoma	durvalumab + savolitinib Sensitive: C3 – Early Trials durvalumab + savolitinib Sensitive : C3	durvalumab + savolitinib Sensitive: C3 – Early Trials durvalumab + savolitinib Sensitive : C3
MET mutation	Non Small Cell Lung Cancer	MET mutation	Non Small Cell Lung Cancer	MTI-31 Sensitive: D – Preclinical MTI-31 Sensitive : D	MTI-31 Sensitive: D – Preclinical MTI-31 Sensitive : D